top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIL17A/hIL17F mice
Strain Name
C57BL/6-Il17atm1(IL17A)Bcgen Il17ftm1(IL17F)Bcgen/Bcgen
Common Name  B-hIL17A/hIL17F mice
Background C57BL/6 Catalog number  120554
Related Genes  IL17A (interleukin 17A); IL17F (interleukin 17F)
NCBI Gene ID
16171,257630

Protein expression analysis

from clipboard

Strain specific IL17A expression analysis in homozygous B-hIL17A/hIL17F mice by ELISA. 
Serum were collected from wild type (WT) mice and homozygous B-hIL17A/hIL17F mice (H/H) stimulated with anti-mCD3ε and anti-mCD28 antibody in vivo, and analyzed by ELISA with species-specific IL17A ELISA kit. Mouse IL17A was detectable in WT mice. Human IL17A was detectable in homozygous B-hIL17A/hIL17F mice (H/H). ND: not detectable. 


Protein expression analysis

from clipboard


Strain specific IL17F expression analysis in homozygous B-hIL17A/hIL17F mice by ELISA. 

Naïve CD4+ T cells were sorted from splenocytes of wild type (WT) mice and homozygous B-hIL17A/hIL17F (H/H) mice, and induced into Th17 cells. Th17 cells were stimulated by PMA and lonomycin. The Th17 cells culture supernatants were collected and analyzed by ELISA with species-specific IL17F ELISA kit. Mouse IL17F was detectable in WT mice. Human IL17F was exclusively detectable in homozygous B-hIL17A/hIL17F mice (H/H). ND: not detectable. 


Analysis of lymph node T cell subpopulations in B-hIL17A/hIL17F mice

from clipboard


Analysis of lymph node T cell subpopulations by FACS.
Leukocytes were isolated from female C57BL/6 and B-hIL17A/hIL17F mice (n=3, 7 week-old). Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8, CD4, and Treg cells in homozygous B-hIL17A/hIL17F mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL17A/hIL17F in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell sub types in lymph node. Values are expressed as mean ± SEM.

Blood routine test in B-hIL17A/hIL17F mice

from clipboard


Complete blood count (CBC).
Blood from female C57BL/6 and B-hIL17A/hILl7F mice (n=5, 8 week-old) was analyzed for CBC. There was no differences among any measurement between C57BL/6 and B-hIL17A/hILl7F mice, indicating that introduction of hIL17A and hIL17F in place of its mouse counterpart does not change blood cell composition and morphology. Values are expressed as mean ± SEM.


Blood chemistry of B-hIL17A/hIL17F mice


from clipboard



Blood chemistry tests of B-hIL17A/hIL17F mice. 
Serum from the C57BL/6 and B-hIL17A/hILl7F mice (n=3, 8 week-old) was analyzed for levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). There was no differences on either measurement between C57BL/6 and B-hIL17A/hILl7F mice, indicating that introduction of hIL17A and hIL17F in place of its mouse counterpart does not change ALT and AST levels or health of liver. Values are expressed as mean ± SEM.



Experimental schedule for induction of psoriasis-like skin lesions and in vivo efficacy of anti-human IL17A and IL17F antibody 

from clipboard

Experimental schedule for induction of psoriasis-like skin lesions in B-hIL17A/hIL17F mice. Mice at 10-12 week-old of age received a daily topical of commercially available IMQ cream on the shaved back for 8 consecutive days to induce psoriasis-like skin lesions. Control mice were treated similarly with vaseline cream. Severity of skin inflammation was daily scored and back skin was collected at the endpoint. IMQ: imiquimod.


In vivo efficacy of anti-human IL17A and IL17F antibody with psoriasis model induced in B-hIL17A/hIL17F mice

from clipboard

IMQ-induced skin inflammation in B-hIL17A/hIL17F mice phenotypically resembles psoriasis. 


Mice (female, 10 week-old, n=5) were scored daily for up to 6 days for body weight and clinical signs of skin inflammation following treatment with imiquimod (IMQ) cream. Mice in each group were treated with different dose of bimekizumab produced in house. Doses are shown in legend. (A) Phenotypical presentation of mouse back skin after 6 days of treatment. (B) Body weight changes during treatment. (C-D) Erythema and scaling score of the back was scored daily on a scale from 0 to 4. Additionally, the cumulative score (erythema plus scaling) is depicted. Values are expressed as mean ± SEM.


In vivo efficacy of anti-human IL17A and IL17F antibody with psoriasis model induced in B-hIL17A/hIL17F mice

from clipboard

Dose dependent effects of antibody on keratinocyte proliferation and inflammatory cell infiltration in IMQ induced psoriasis-like skin lesions in B-hIL17A/hIL17F mice. 
Back skin was collected at the endpoint and stained with Hematoxylin and eosin (H&E). (A) H&E staining of the back skin of mice. (B) Epidermal thickness of the mice. (C) Histological changes were scored on a scale from 0 to 11. Results indicated that bimekizumab (in house) significantly reduced psoriasis-like skin lesions in B-hIL17A/hIL17F mice, confirming that B-hIL17A/hIL17F mice is a powerful model for in vivo evaluation of anti-human IL17A and IL17F antibody.